Physician profile
Kacie E Wood
NPI 1568838746
$2,763.18
in general payments reported to CMS, 2019-2025
31 companies · $154 in 2025
The $154 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $57.34 · 2022: $481 · 2023: $1,287 · 2024: $784 · 2025: $154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,224.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $521.54 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $285.13 | 2022-2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $242.03 | 2022-2024 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $237.49 | 2022-2024 | |
| Novo Nordisk INC | $227.04 | 2021-2023 | Ozempic |
| Lilly USA, LLC | $156.68 | 2022-2024 | Mounjaro, Jardiance, Zepbound |
| Neurocrine Biosciences, INC. | $108.53 | 2022-2024 | Ingrezza |
| Shield Therapeutics INC | $89.00 | 2023-2025 | Accrufer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $85.75 | 2023 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $74.16 | 2023-2025 | Airsupra, Breztri |
| Teva Pharmaceuticals USA, INC. | $69.40 | 2022-2023 | Austedo Xr |
| Amgen INC. | $58.99 | 2023-2024 | Otezla, Repatha |
| Axsome Therapeutics, INC. | $51.77 | 2024 | Auvelity |
| Xeris Pharmaceuticals, INC. | $50.10 | 2024 | Gvoke Hypopen, Keveyis |
| Biohaven Pharmaceutical Holding Company LTD. | $49.77 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $45.62 | 2023 | Daybue |
| Scilex Pharmaceuticals INC. | $44.53 | 2023 | Ztlido |
| Exact Sciences Corporation | $43.88 | 2024 | Cologuard Collection Kit |
| Ardelyx, INC. | $42.93 | 2023-2024 | Ibsrela |
| Alkermes, INC. | $42.43 | 2022-2023 | Aristada, Lybalvi |
| Dexcom, INC. | $37.36 | 2022-2024 | Dexcom G6 Transmitter |
| Ucb, INC. | $26.49 | 2023 | Briviact |
| Indivior INC. | $23.00 | 2024 | Sublocade |
| Takeda Pharmaceuticals U.S.A., INC. | $22.53 | 2024 | Trintellix |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $21.03 | 2025 | |
| Corcept Therapeutics | $19.00 | 2023 | Korlym |
| Glaxosmithkline, LLC. | $18.42 | 2023 | Trelegy Ellipta |
| Hologic Sales and Service, LLC | $17.50 | 2022 | |
| Janssen Pharmaceuticals, INC | $17.26 | 2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.13 | 2023 | |
| Phathom Pharmaceuticals, INC. | $16.69 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kacie Wood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.